(Q37980690)

26 August 2017

Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason (English)

1 reference

26 August 2017

0 references

1 reference

1 reference

congenital heart disease

1 reference

Anjan S Batra

1

1 reference

PubMed ID

22298228

26 August 2017

Mark E Alexander

series ordinal

2

1 reference

PubMed ID

22298228

26 August 2017

Michael J Silka

series ordinal

3

1 reference

26 August 2017

1 March 2012

1 reference

26 August 2017

1 reference

26 August 2017

33

1 reference

26 August 2017

3

1 reference

26 August 2017

394-401

1 reference

https://scigraph.springernature.com/pub.10.1007/s00246-012-0162-6

26 August 2017

0 references

cites work

How common is attention-deficit/hyperactivity disorder? Incidence in a population-based birth cohort in Rochester, Minn

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0162-6

A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0162-6

Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0162-6

Short-term cardiovascular effects of methylphenidate and adderall

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0162-6

Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0162-6

Sudden death and use of stimulant medications in youths.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0162-6

Prevalence of congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0162-6

Late neurodevelopmental outcome after repair of total anomalous pulmonary venous connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0162-6

Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0162-6

Cardiovascular events and death in children exposed and unexposed to ADHD agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0162-6

Inattention, hyperactivity, and school performance in a population of school-age children with complex congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0162-6

Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0162-6

Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0162-6

Stimulants and sudden death: what is a physician to do?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0162-6

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0162-6

Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: A statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association

21 January 2018

1 reference

12 December 2020

Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in

1 reference

12 December 2020

Cardiovascular risk screening before starting stimulant medications and prescribing practices of canadian physicians: impact of the Health Canada advisory

1 reference

12 December 2020

Classifying recommendations for clinical practice guidelines

1 reference

12 December 2020

Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study.

1 reference

12 December 2020

Neurodevelopmental outcome and lifestyle assessment in school-aged and adolescent children with hypoplastic left heart syndrome

1 reference

12 December 2020

Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder

1 reference

12 December 2020

10.1007/S00246-012-0162-6

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22298228